In Vitro Diagnostics 2017

conference overview

SMi is proud to announce the launch of their In-Vitro Diagnostics (IVD) event to London in 2017!
 

With the current uncertain regulatory landscape in the IVD industry, What does the future hold for companies of the IVD industry? A recent report describes total revenues of the the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027.
 

SMi's In-Vitro Diagnostics (IVD) will prepare you for the challenging times ahead and how to comply with regulatory requirements to ensure direct access to market ensuring the continued growing demand for use and innovation of IVDs over the next decade and beyond.
 

Topics of discussion the latest update on the IVD regulation, the implementation of the Qualified Person (QP) as well as the increase in requirements for clinical evidence.
 

benifits of attending

• Hear direct feedback and experiences from the FDA on In Vitro registration in USA
   
• Direct your questions to ourexpert panel of Notified Body representatives including BSI, UL, LRQA, TUV SUD, LNE/GMED and TÜV Rheinland
   
• Learn how the change in classifications will impact industry with UL
   
• Hear insights from Ortho Clinical Diagnostics on the increased requirements for post market surveillance
   
• Examine the Medical Device Single Audit Program (MDSAP) with Berlin Heart GmbH
   

Who should attend

Leading IVD manufacturers, regulators, diagnostic companies to allow you to benchmark your companies strategies and allow for an effective industry specific experience exchange.
 

Adams Business Associates; Alere International; Alere UK (Rebranded from Inverness Medical UK); AstraZeneca; Bayer A G; BIOAXXESS Technology; Biokit S A; BioKit SA; Boehringer Ingelheim Microparts Gmbh; Cambridge Isotope Laboratories Inc.; Euro Diagnostica; Fleet Bioprocessing Ltd; Index Ventures; Innovate UK (formerly:Technology Strategy Board); Integrated Medicines; Irish Medicines Board; Life Technologies; Medical Device Consultancy; National Genetics Reference Lab, Manchester; NHS Innovations London; NHS Institute for Innovation and Improvement; Pharma Ventures; Point-2-Point Genomics Ltd; QuantumDX; Quotient Bioresearch; Roche Diagnostics Ltd; Royal Free Hospital; Scientia Advisors; Simon-Kucher & Partners; Technology Networks; Unilabs France; University of Birmingham; University of Edinburgh;